The
Helsinki Report A double-blind study researched the weight-reducing efficacy of chitosan over a two to four week period. The study was performed at the ARS Medicina in Helsinki, Finland from mid-August to October of 1994.
The primary objective of this study was to measure the weight reduction efficacy of the
chitosan in Chitosan Plus, but, secondarily, the researchers also wanted to look at the
effect on elevated blood pressure (hypertension).
The initial length of the study was designed for 14 days, but some of the patients
decided to continue and were monitored for a longer period of time. The doctors
controlling the study performed weekly controlled visits. At each visit, the patients were
monitored for strict dietary control and to ensure they had been taking the chitosan
capsules as prescribed. The weight and blood pressure parameters were measured at each
visit. Each patient was to take 4 capsules of of chitosan twice daily, 4 before lunch and
4 before dinner each day. Each patient was cleared by medical examination in order to
participate in this study. Thirty patients started the study, but six withdrew and four
others were found to not be sufficiently overweight to participate in this study. Of the
remaining 20 patients, all but two fulfilled the four-week study period, eight were placed
in the active group, and ten in the placebo group.
Both groups showed hypertension in their members, and both groups had a homogeneity
matched for body weight, height and body mass index. The placebo group members were an
average of six years younger in age, while the chitosan group members had an average age
of 50. If anything, this would help the placebo group in terms of superior response in
terms of losing weight. However, as we shall see, the results were significantly in favor
of chitosan. |